Interviewees reported that the absence of intellectual property rights by the MNI over discoveries derived from C-BIG biobank materials or data is a key draw for partners. Nevertheless, there are dissenters. Some interviewees and some of the MNI’s potential industry collaborators stated that they will proceed with care, ‘testing the waters’ as they engage in open practices. Others, however, including the multinational biotechnology company Thermo Fisher Scientific, have rapidly secured open-science-based partnerships with the MNI, noting a shared objective in improving the accountability and efficiency of research. Thermo Fisher stated that the MNI’s open science policy will greatly accelerate the development and commercialization of more relevant reagents, while allowing the sharing of the experimental data with the research community. However, they underlined that maximizing the benefits of open science depends on broad community adoption.